A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to assess the pigmentation in the trabecular meshwork of patients who had been treated for at least 2 years with TRAVATAN compared with patients without exposure (or less than 1 month) to a prostaglandin analogue (PGA).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions; Travoprost

Criteria

Inclusion Criteria:

• Diagnosis of open-angle glaucoma without pseudoexfoliation or pigment dispersion component;

• Either two or more years of dosing with Travatan, or no prior exposure (less than 1 month) to a topical ocular prostaglandin;

• Requires a trabeculectomy;

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Pseudoexfoliation or pigment dispersion;

• History of chronic or recurrent severe inflammatory eye disease;

• History of or current ocular infection or ocular inflammation within the past 3 months in either eye;

• Greater than one month but less than two years of exposure to TRAVATAN;

• Pregnant, breast-feeding, not using highly effective birth control;

• Other protocol-defined exclusion criteria may apply.